Communiqués Taysha Gene Therapies, Inc.

Actions

TSHA

US8776191061

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
2,24 ^USD	+3,46%		-24,32%	+26,55%

26/06	Taysha Gene Therapies fixe le prix d'une offre de 75 millions de dollars d'actions et de bons de souscription préfinancés ; les actions chutent	MT
26/06	Mise à jour sectorielle : Les actions du secteur de la santé mélangées avant la cloche mercredi	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants	26/06	AQ
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	26/06	AQ
TSHA 102 in clinical evaluation for Rett syndrome: Cohort one data from the REVEAL Phase 1/2 Adolescent Adult and Pediatric trials	18/06	PU
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome	18/06	AQ
Taysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting	12/06	AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	07/06	AQ
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update	14/05	AQ
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14	07/05	AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	03/05	AQ
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome	02/05	AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	05/04	AQ
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates	19/03	AQ
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19	14/03	AQ
Taysha Gene Therapies : March 2024 Corporate Presentation	08/03	PU
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	01/03	AQ
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome	29/02	AQ
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs	15/02	AQ
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	02/02	AQ
Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference	22/01	AQ
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome	10/01	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Taysha Gene Therapies, Inc.

Actions

TSHA

US8776191061

Communiqués

Filtres